They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.
Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.
The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.
In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.
Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.
The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.
The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.
In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.
The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
This content was published on
On Saturday the Lake Geneva, Valais and Basel regions are expected to record the first tropical day of the year, with temperatures exceeding 30°C.
This content was published on
The Swiss economy saw the clouds that had gathered over its prospects lift somewhat in May. However, the KOF economic barometer is still below its long-term average.
Direct operations too dangerous in Swiss landslide valley
This content was published on
By Friday morning 365 people had been forced to leave their homes because of Wednesday's landslide in the Swiss village of Blatten.
Franco-Swiss raclette war set to be settled on Sunday
This content was published on
The battle for the world's largest raclette will be transformed on Sunday in Saint-Gingolph, canton Valais, into a raclette of friendship served at the border.
Flood risk threatens Swiss valley after ‘millennium event’ glacier collapse
This content was published on
Two days after a gigantic avalanche of ice, mud and debris buried much of the village of Blatten in canton Valais, the danger is not over.
Situation in Swiss landslide valley remains unstable
This content was published on
Authorities in Valais said on Thursday that it was still too dangerous to begin clear-up activities around the village of Blatten.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis and Microsoft to develop drugs using AI
This content was published on
Novartis and Microsoft have signed a five-year partnership aimed at transforming the Basel-based pharma’s business using AI.
Gaps found in opioid prescription oversight in Switzerland
This content was published on
In the wake of the opioid crisis in the US, some medical professionals in Switzerland are warning about over-prescription of oxycodone drugs.
Swiss pharmaceutical firm lets dogs die cruel death
This content was published on
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, says a report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.